期刊文献+

膦甲酸钠治疗112例带状疱疹的疗效和安全性回顾性分析 被引量:17

Efficacy and Safety of Foscarnet Sodium in the Treatment of 112 Cases of Herpes Zoster
下载PDF
导出
摘要 目的探讨膦甲酸钠氯化钠注射液治疗带状疱疹的疗效和安全性。方法回顾分析2007年1月-2013年1月在本科住院应用膦甲酸钠氯化钠注射液治疗带状疱疹的患者的病历资料,记录患者一般情况,症状体征和给药方式,以及疗效评价参数,包括:皮疹控制天数,皮疹大部好转天数,皮疹痊愈天数,疼痛开始缓解天数,疼痛大部消退天数,用药前和用药7d的疼痛程度视觉模拟评分(visual analogue scale,VAS)以及不良事件等。对数据进行统计学分析和分组比较。结果共采集病例205例,符合入组条件112例。疗效评价:平均皮疹控制天数2.3d,平均皮疹好转天数6.0d,平均皮疹痊愈天数10.6d。平均疼痛开始缓解天数2.8d,平均疼痛大部分消退天数8.7d。用药7d VAS平均改善56.53%,有效率93.14%。每日1次与2次给药组之间及男女性别组间疗效差异无统计学意义。低龄组疗效指标均优于高龄组。中低VAS组疗效指标均优于高VAS组。不良反应发生率3.57%,无严重不良反应。结论膦甲酸钠氯化钠注射液治疗带状疱疹有较好疗效,可以较快控制皮疹和改善疼痛症状。在优化给药方式前提下,膦甲酸钠氯化钠注射液治疗带状疱疹有较好的安全性。 Objective To investigate the efficacy and safety of foscarnet sodium and sodium chloride injection treatment of herpes zoster. Methods Retrospective analyzes the medical records of hospitalized patients of herpes zoster treated with foscarnet sodium and sodium chloride injection in our department from 2007 January to 2013 January. Collect patients' clinical data including the general condition, treatment, and efficacy evaluation parameters including the number of days of rash control, of rash improve, and of rash healing, the number of days of pain began to relieve, and of pain relieve significantly, the pain visual analog scale (VAS) score before treatment and the 7 days after treatment. The data were statistically analyzed and compared in groups. Results A total of 205 cases were collected, 112 cases entered the treatment groups. The mean days of rash control,of rash improve,and of rash healing were 2.3d,6.0d and 10.6d respectively. The a mean days of pain beginning,and of pain relief were 2.8d and 8.7d respectively. At the 7th day the average improvement of VAS was 56.53%, and total effective rate was 93.14%. There were no significant differences between once daily dosing group and twice daily dosing group, and sex groups. Efficacy evaluation index in younger age group were all superior to the aging groups, in the low VAS group were all superior to the high VAS group. The adverse reaction rate was 3.57%. No serious adverse reactions were observed. Conclusion Fos- carnet sodium and sodium chloride injection have a good effect for herpes zoster, and can quickly control the rash and improve the pain. Under the optimal administration,foscarnet sodium and sodium chloride injection has high safety in treatment of herpes zoster.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2014年第12期1238-1240,共3页 The Chinese Journal of Dermatovenereology
关键词 膦甲酸钠 带状疱疹 治疗 Foscarnet Herpes zoster Treatment
  • 相关文献

参考文献8

  • 1Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activi- ty, pharmacokinetic properties and therapeutic use in immunocompro- mised patients with viral infections [ J ]. Drugs, 1994,48 (2) :199 -226.
  • 2Karoline B, Jindrich C, Jonas SC. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet [ J ]. Med Microbiol Immuuo1,2011,200 ( 3 ) : 193 - 202.
  • 3Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing fos- carnet with vidarabine for acyclovir-resistant mucocutaneous herpes sim- plex in the acquired immunodeficiency syndrome[J]. The AIDS Clinical Trials Group. N Engl J Med,1991,325(8) : 551 -555.
  • 4Gerard L, Salmon-Ceron D. Pharmacology and clinical use of foscarnet [ J ]. International Journal of Antimicrobial Agents, 1995,5 (4) : 209 - 217.
  • 5剡建平,王玲.两种剂量的伐昔洛韦分散片治疗带状疱疹临床疗效对照[J].中国皮肤性病学杂志,2010,24(3):234-235. 被引量:11
  • 6周村建,王莉,郭在培,涂亚庭,卢念祖,郝飞.不同剂量和疗程伐昔洛韦治疗带状疱疹的多中心随机双盲对照研究[J].临床皮肤科杂志,2007,36(7):420-422. 被引量:19
  • 7Jacobson MA. Review of the toxicities of foscarnet [ J]. AIDS, 1992,5 (suppl 1) :S11 -17.
  • 8李丹丹,解倩,王悦,赵荣生.膦甲酸钠相关急性肾衰竭[J].药物不良反应杂志,2012,14(5):317-319. 被引量:14

二级参考文献18

  • 1金伟华,王晓蕙,陈华.阿昔洛韦静脉滴注导致急性肾衰[J].药物不良反应杂志,2006,8(5):385-386. 被引量:3
  • 2周村建,王莉,郭在培,涂亚庭,卢念祖,郝飞.不同剂量和疗程伐昔洛韦治疗带状疱疹的多中心随机双盲对照研究[J].临床皮肤科杂志,2007,36(7):420-422. 被引量:19
  • 3Beauchamp LM,Or GF,de Miranda P,et al.Amino acid ester prodrugs of acyclovir[J].Antivlral Chem Chemother,1992,3:157-164.
  • 4Waller S,Btum MR,Douoette M,et al.Pharmamkinetics ot the acyclovir prodruy Valaciclovir afterescalating single and multipledose administratiort to normal Vohmteers[J].CA in Pharmaml Ther,1993,54:595-605.
  • 5Lin WR,Lin HH,Lee SS,et al.Comparative study of the eficacyand safety of valaciclovir vepsus acyclovir in the treatment of herpeszoster[J].J Microbiol Irnnmnol Infect,2001,34(2):138-142.
  • 6Colin J,Pnsant 0,Cochener B,et al.Comparison of the eficacyand safety of valaciclovir and acyclovir for the treatm ent of herpeszoster ophthalmicus[J].Ophthalmology,2000,107(8):1507-1511.
  • 7Ormrod D,Goa K.Valaciclovir:a review of its use in the management of herpes zoster[J].Drugs,2000,59(6):1317-1340.
  • 8Lin WR,Lin HH,Lee SS,et al.Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster[J].J Microbiol Immunol Infect,2001,34(2):138-142.
  • 9Weller S,Blum MR,Doucette M,et al.Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers[J].Clin Pharmacol Ther,1993,54(6):595-605.
  • 10Choudhury D,Z Ahmed. Drug-associated renal dysfunction and injury[J].Nephrology,2006,(02):80-91.

共引文献40

同被引文献127

引证文献17

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部